CDK4 and breast carcinoma: Our unexpected findings contrast with the initial application of CDK4/6 inhibitors in treating ER+ breast cancers that are often characterized with dysregulated CDK4/6 activation15–19,33–35, where the oncogenic addiction to cyclin D1 is being targeted.